Edited by:
Paolo Spagnolo, MD, PhD, University Hospital of Padova, University of Padova, Italy
Argyrios Tzouvelekis, MD, PhD, University of Patras, Greece
This collection is no longer accepting submissions.
Respiratory Research is calling for submissions to our collection on Pulmonary fibrosis: new insights.
This Collection supports and amplifies research related to SDG 3.
Image credit: Paolo Spagnolo
Cough remains a persistent symptom in patients with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). To inform future research, treatment and care models, we conducted the first...
Sleep-disordered breathing (SDB) is a major comorbidity in idiopathic pulmonary fibrosis (IPF) and is associated with a poor outcome. There is a lack of knowledge regarding the impact of SDB treatment on IPF. ...
Idiopathic Pulmonary Fibrosis (IPF) represents a chronic and progressive pulmonary disorder distinguished by a notable mortality rate. Despite the elusive nature of the pathogenic mechanisms, several signaling...
In familial pulmonary fibrosis (FPF) at least two biological relatives are affected. Patients with FPF have diverse clinical features.
Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with different disease trajectories. Progression (PF-ILD) occurs in up to 50% of patients and is associated with ...
Although some studies have indicated that Psoriasis could contribute to the risk of idiopathic pulmonary fibrosis (IPF), no study has reported a clear causal association between them. Our aim was to explore th...
Idiopathic pulmonary fibrosis (IPF) is a progressive disease associated with high mortality. Low muscle mass, frailty and sarcopenia lead to functional impairment that negatively impact quality of life and sur...
Breath testing using an electronic nose has been recognized as a promising new technique for the early detection of lung cancer. Imbalanced data are commonly observed in electronic nose studies, but methods to...
Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with more than 200 entities and relevant differences in disease course and prognosis. Little data is available on...
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) with unknown etiology, characterized by sustained damage repair of epithelial cells and abnormal activation of fibroblasts, ...
Several observational studies have found that physical inactivity and sedentary time are associated with idiopathic pulmonary fibrosis (IPF) risk. However, the causality between them still requires further inv...
Mediastinal lymph node enlargement is prevalent in patients with idiopathic pulmonary fibrosis (IPF). Studies investigating whether this phenomenon reflects specific immunologic activation are lacking.
Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation. Recognition of ILD is often late, causing delay which has been associat...
The role of the immune system in the pathobiology of Idiopathic Pulmonary Fibrosis (IPF) is controversial.
Respiratory Research is calling for submissions to our collection on Pulmonary fibrosis: new insights. The field of pulmonary fibrosis has gone through substantial changes in recent years, with several traditional views on disease pathogenesis and treatment being challenged and replaced by more convincing concepts. The collection seeks manuscripts that address the diagnosis, characterization and management of pulmonary fibrosis, with emphasis on novel concepts of disease pathogenesis, predictors of disease behavior and response to treatment and developmental drugs.
This Collection welcomes submission of Research Articles, Data Notes, Case Reports, Study Protocols, and Database Articles.
Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Pulmonary fibrosis: new insights" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.
The Editors have no competing interests with the submissions which they will handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.